Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Stopped since the CheckMate816 study is published in NEJM, enrolling patients becomes difficult

Conditions

• Non Small Cell Lung Cancer

Interventions

• DRUG: Carboplatin
• DRUG: Pemetrexed or Nab-paclitaxel
• DRUG: PD-1 antibody

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China